Pharmaceutical portfolio decision-making is facing structural pressure. Patent expirations, rising development costs, ...

Pharma R&D leaders in Europe are facing a rare convergence of pressures: a historic patent cliff, tightening EU/UK pricing ...

Medical technology company Boston Scientific became the target of a cyberattack this week, which disrupted some of its IT ...

While obesity may be a fast-growing cost area, it's far from the largest -- only 10% of employers surveyed put it in their ...

Jazz Pharmaceuticals has been granted US approval for two combinations of its cancer drug Ziihera for people with advanced ...

Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road after ...

Melbourne, Australia-based biotech Entropy Neurodynamics has signed a Pre-Clinical Trial Agreement (Pre-CTA) with the ...

Revolution Medicines' Rasonque (daraxonrasib), the RAS inhibitor that received a standing ovation at ASCO for its doubling of overall survival in patients with metastatic pancreatic ductal ...

Europe. Whilst long recognised as Europe's largest partnering conference, it's now expanding to become the continent's most ...

Cambridge, UK-based Neurocrine Biosciences - partnered with Japan’s Nxera Pharma - has announced it has received IND ...

Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity ...

Roche has won US FDA clearance for a blood test that could move Alzheimer’s biomarker testing further into primary care, ...